Compare LFTO & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFTO | BLLN |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 5.8B |
| IPO Year | 2026 | N/A |
| Metric | LFTO | BLLN |
|---|---|---|
| Price | $22.76 | $127.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $126.71 |
| AVG Volume (30 Days) | ★ 671.9K | 594.9K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | N/A | $30.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.50 | $61.96 |
| 52 Week High | $27.94 | $138.70 |
| Indicator | LFTO | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 58.49 |
| Support Level | $21.77 | $79.07 |
| Resistance Level | $25.96 | $138.70 |
| Average True Range (ATR) | 1.46 | 7.25 |
| MACD | -0.10 | -0.92 |
| Stochastic Oscillator | 29.68 | 70.21 |
Liftoff Mobile Inc is a marketing and retargeting platform that helps businesses maximize revenue through machine learning-powered solutions. Its AI-powered platform is designed to serve all verticals in the app ecosystem and is fully integrated to drive differentiated advertising performance for its customers across the app economy. The company deliver profitable users for app advertisers and help to maximize advertising revenue for apps that monetize with ads. Its solutions include: Marketers; Agencies; DSPs; Publishers; and Mobile Gaming.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.